Join

Compare · CGC vs KRBP

CGC vs KRBP

Side-by-side comparison of Canopy Growth Corporation (CGC) and Kiromic BioPharma Inc. (KRBP): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both CGC and KRBP operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
  • CGC is the larger of the two at $2.86B, about 189.2x KRBP ($15.1M).
  • CGC has hit the wire 4 times in the past 4 weeks while KRBP has been quiet.
  • CGC has more recent analyst coverage (19 ratings vs 0 for KRBP).
MetricCGCKRBP
Company
Canopy Growth Corporation
Kiromic BioPharma Inc.
Price
$1.01-0.98%
$1.48-1.33%
Market cap
$2.86B
$15.1M
1M return
-10.57%
-
1Y return
-32.33%
-
Industry
Medicinal Chemicals and Botanical Products
Medicinal Chemicals and Botanical Products
Exchange
NYSE
NASDAQ
IPO
2020
News (4w)
4
0
Recent ratings
19
0
CGC

Canopy Growth Corporation

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flowers, oils and concentrates, and softgel capsules. It offers its products under the Tweed, Quatreau, Deep Space, Spectrum Therapeutics, First & Free, TWD, This Works, BioSteel, DNA Genetics CraftGrow, Tokyo Smoke, DOJA, Van der Pop, and Bean & Bud brands. The company also provides growth capital and a strategic support platform that pursues investment opportunities in the global cannabis sector. Canopy Growth Corporation has a clinical research partnership with NEEKA Health Canada and NHL Alumni Association to examine the efficacy of CBD-based therapies as part of the mitigation of persistent post-concussion symptoms. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.

KRBP

Kiromic BioPharma Inc.

Kiromic BioPharma, Inc., a target discovery and gene editing company, focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1; and chimeric gamma delta PD1 T cell switch receptor therapy. It has license agreements with Mercer University; CGA 369 Intellectual Holdings, Inc.; and Longwood University, as well as research and development collaboration agreements with Molipharma, S.R.L. and Leon Office (H.K.). The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

Latest CGC

Latest KRBP